Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201011828 Principal Investigator: DiPersio, John
Title: Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination with Daunorubicin and Cytarabine in Patients with Poor-risk, Acute Myelogenous Leukemia (AML)
Phase: I Disease Site: Myeloid and Monocytic Leukemia
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purposes of this research study are to determine the maximum dose of AT-406 that can be safely given in combination with cytarabine and daunorubicin to humans. Other purposes are to determine how the drug AT-406 is broken down in the body, and to see if there are any observations that we can make to help determine how AT-406 works. Any side effects that are experienced from taking AT-406 will be studied in an effort to make sure that this drug is safe to take.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)